Last reviewed 2026-05-14 · How we verify

HS-25 and Atorvastatin

HS-25 is a combination therapy where HS-25 (an investigational agent) is co-administered with atorvastatin, a statin that inhibits HMG-CoA reductase to lower cholesterol.

HS-25 is a combination therapy where HS-25 (an investigational agent) is co-administered with atorvastatin, a statin that inhibits HMG-CoA reductase to lower cholesterol. Used for Hyperlipidemia or cardiovascular disease (specific indication not publicly confirmed).

At a glance

Mechanism of action

Atorvastatin reduces LDL cholesterol and triglycerides by inhibiting the rate-limiting enzyme in cholesterol synthesis. HS-25's specific mechanism is not publicly disclosed, but the combination is being evaluated in Phase 3 trials, likely for cardiovascular or metabolic indications. The exact mechanism of HS-25 and its synergy with atorvastatin requires access to clinical trial protocols.

Approved indications

• Hyperlipidemia or cardiovascular disease (specific indication not publicly confirmed)

Common side effects

• Muscle pain or myalgia
• Elevated liver enzymes
• Headache

Key clinical trials

• Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases (PHASE3)
• Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HS-25 and Atorvastatin CI brief — competitive landscape report
• HS-25 and Atorvastatin updates RSS · CI watch RSS
• Zhejiang Hisun Pharmaceutical Co. Ltd. portfolio CI